Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kelly Johnson

Nurse Practitioner, Family Huntington, WV Nurse Practitioner

NPI 1780083519 CMS profile 10593960

1600 Medical Center Dr Ste B500, Huntington, WV 25701

Open in the dashboard

General payments

$6,761

450 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kelly Johnson of Huntington, WV is reported in the CMS Open Payments database as having received $6,761 across 450 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,386 145
2024 General $1,255 114
2023 General $1,587 108
2022 General $1,260 38
2021 General $1,273 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Johnson
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kelly Johnson were reported at $1,386. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kelly Johnson Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,273 $124 $35–$379 $132
2022 $1,260 $141 $44–$430 $149
2023 $1,587 $154 $49–$476 $160
2024 $1,255 $165 $51–$504 $164
2025 $1,386 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,081 249 payments
  2. Abbott Laboratories $872 23 payments
  3. Pfizer Inc. $654 100 payments
  4. Biohaven Pharmaceutical Holding Company Ltd. $596 11 payments
  5. Medtronic, Inc. $210 9 payments
  6. Janssen Pharmaceuticals, Inc $201 4 payments
  7. UCB, Inc. $180 11 payments
  8. Biohaven Pharmaceuticals, Inc. $168 5 payments
  9. Alexion Pharmaceuticals, Inc. $150 2 payments
  10. E.R. Squibb & Sons, L.L.C. $90 1 payment
  11. Other $558 35 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,485 443 payments
  2. Travel and Lodging $1,126 5 payments
  3. Education $150 2 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $2,318 190 payments
  2. QULIPTA $2,179 183 payments
  3. NURTEC ODT Primary Care $764 16 payments
  4. NURTEC ODT Pain $654 100 payments
  5. ZAVZPRET $619 96 payments
  6. Proclaim IPG $481 1 payment
  7. Infinity DBS Pulse Generators $233 18 payments
  8. PERCEPT PC BRAINSENSE $175 7 payments
  9. ULTOMIRIS $150 2 payments
  10. INFINITY $138 3 payments
  11. Other $1,396 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,865

Median for Nurse Practitioner: 389

Drug cost

$513,213

Median for Nurse Practitioner: $21,885

Branded share of claims

37.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 12 $151,016
Copaxone Glatiramer Acetate Brand 13 $74,600
Nurtec Odt Rimegepant Sulfate Brand 52 $61,807
Ubrelvy Ubrogepant Brand 51 $61,184
Briviact Brivaracetam Brand 15 $30,355
Aimovig Autoinjector Erenumab-Aooe Brand 35 $28,730
Ajovy Autoinjector Fremanezumab-Vfrm Brand 25 $17,373
Emgality Pen Galcanezumab-Gnlm Brand 19 $15,955
Botox Onabotulinumtoxina Brand 13 $13,919
Ajovy Syringe Fremanezumab-Vfrm Brand 17 $11,934

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$18,708

Medicare's payments for the services billed

Medicare patients

188

Average age 70

Services billed

353

115 women, 73 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Depression 43%
Ischemic heart disease 32%
Diabetes 31%
Chronic kidney disease 25%
Atrial fibrillation 23%
COPD 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $440
$440 51 —
QULIPTA
  • AbbVie, Inc. $414
$414 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $100
$100 — —
NURTEC ODT
  • PFIZER INC. $99
$99 52 —
ZAVZPRET
  • PFIZER INC. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

450 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record